Margherita Bigossi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margherita Bigossi has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Moneeza Kalhan Siddiqui
Wolfson Institute of Population Health, Queen Mary University of London
7 shared publications - Sam Hodgson
Wolfson Institute of Population Health, Queen Mary University of London
5 shared publications - Sarah Finer
Wolfson Institute of Population Health, Queen Mary University of London, London, UK
5 shared publications - David A. van Heel
Blizard Institute, Queen Mary University of London, London, UK
4 shared publications Viswanathan Mohan
Madras Diabetes Research Foundation
4 shared publications- Adem Y. Dawed
Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK
3 shared publications
Latest Publications
- Open Access
An ancestry-enriched PIEZO1 missense variant biases HbA1c-based diagnosis of prediabetes and type 2 diabetes in South Asians
Background: Glycated haemoglobin (HbA1c) underpins type 2 diabetes (T2D) and prediabetes management worldwide and reflects both glycaemia and erythrocyte biology. A missense variant in PIEZO1 (rs563555492 T ), carried by 1 in 12 south Asians, has been associated with a nonglycemic reduction in HbA1c. We aimed to further characterise this association and evaluate its clinical consequences. Methods: We undertook genetic and linked health data analyses across two cohorts: 19,898 (37.4% female) South Indians from the Madras Diabetes Research Foundation (MDRF) and 43,011 (54.4% female) British Bangladeshis and British Pakistanis in Genes & Health. In MDRF, we tested associations with glycaemic and erythrocytic traits using additive genetic models. In Genes & Health we modelled diagnosis of prediabetes, T2D, and diabetic eye disease using flexible parametric survival models. Ten-year absolute risks were estimated for a population aged 40-50 years. Findings: PIEZO1 rs563555492 T was associated with erythrocytic traits and lower HbA1c, but not with fasting glucose, postprandial glucose, or C-peptide. This variant reduced risk of prediabetes (HR 0·63, 95% CI 0·58-0·69) and T2D (0·85, 0·78-0·93) diagnosis, and increased risk of diabetic eye disease among individuals with T2D (1·20, 1·01-1·43). Modelling suggested approximately 1,019 missed prediabetes and 303 missed T2D diagnoses per 100,000 adults over 10 years. Interpretation: An ancestry enriched PIEZO1 variant is associated with lower HbA1c independent of glycaemia, reduced prediabetes and T2D diagnosis suggesting delayed detection, and increased complication risk. Reliance on HbA1c may systematically underestimate glycaemic risk in a substantial minority of south Asians. Funding: The Wellcome Trust; NIHR Research in Context: Evidence before this study: We searched PubMed from database inception to Nov 1, 2025, for studies examining PIEZO1, Glycated Haemoglobin (HbA1c) and type 2 diabetes (T2D) related outcomes. Search terms included “PIEZO1”, “haemoly*”, “hemol*”, “erythrocyte*”, “HbA1c”, “glycated haemoglobin”, “glycated hemoglobin”, “type 2 diabetes”, “prediabetes”, “retinopathy”, and related terms. HbA1c is widely used to guide prevention, diagnosis, and management of T2D, but variants affecting erythrocyte structure or lifespan can alter its relationship with glycaemia. A missense variant in PIEZO1 (rs563555492 T ), carried by one in twelve south Asians, has been associated with lower HbA1c and erythrocytic biomarkers without differences in fasting glucose and with older age at T2D diagnosis, suggesting delayed diagnosis in UK-based cohorts. However, uncertainties remain. Associations have not been replicated outside the UK to confirm generalisability. Experimental animal models suggest PIEZO1 channels may influence pancreatic insulin secretion, but this has not been evaluated in human cohorts. Finally, the potential clinical and health-economic consequences associated with this variant remain largely unexplored. Added value of this study: We replicated associations between rs563555492 T , lower HbA1c, and erythrocytic changes in a geographically distinct south Asian cohort based in South India. We found no association with fasting glucose, postprandial glucose, or C-peptide concentrations, supporting a predominantly erythrocytic mechanism. We examined the clinical and economic consequences of this variant on south Asians in a large UK population-based cohort, following introduction of HbA1c-based diagnostic criteria. Carriers experienced delayed diagnosis of prediabetes and T2D, and there was some evidence of increased risk of diabetic eye disease. In a modelled population aged 40-50 years, the variant was associated with approximately 1,019 missed prediabetes diagnoses and 303 missed T2D diagnoses per 100,000 adults over 10 years. Because prediabetes diagnosis initiates referral to prevention programmes, missed diagnoses represent lost opportunities for disease prevention. In a UK NHS setting, we estimated the associated opportunity cost to be between £970,000 - £1,390,000 per 100,000 individuals over a 10-year horizon. Implications of all the available evidence: A south Asian ancestry enriched PIEZO1 variant can disrupt the relationship between HbA1c and glycaemia and delay detection of prediabetes and T2D. Reliance on HbA1c alone may underestimate glycaemic risk in a substantial minority of individuals of south Asian ancestry, with potential implications for prevention strategies, risk of complications and health care costs. Alternative biomarkers of glycaemia or individualisation of HbA1c may help ensure timely and accurate diabetes detection in populations where this variant is common.
Open AccessAn ancestry-enriched PIEZO1 missense variant biases HbA1c-based diagnosis of prediabetes and type 2 diabetes in South Asians
Background: Glycated haemoglobin (HbA1c) underpins type 2 diabetes (T2D) and prediabetes management worldwide and reflects both glycaemia and erythrocyte biology. A missense variant in PIEZO1 (rs563555492 T ), carried by 1 in 12 south Asians, has been associated with a nonglycemic reduction in HbA1c. We aimed to further characterise this association and evaluate its clinical consequences. Methods: We undertook genetic and linked health data analyses across two cohorts: 19,898 (37.4% female) South Indians from the Madras Diabetes Research Foundation (MDRF) and 43,011 (54.4% female) British Bangladeshis and British Pakistanis in Genes & Health. In MDRF, we tested associations with glycaemic and erythrocytic traits using additive genetic models. In Genes & Health we modelled diagnosis of prediabetes, T2D, and diabetic eye disease using flexible parametric survival models. Ten-year absolute risks were estimated for a population aged 40-50 years. Findings: PIEZO1 rs563555492 T was associated with erythrocytic traits and lower HbA1c, but not with fasting glucose, postprandial glucose, or C-peptide. This variant reduced risk of prediabetes (HR 0·63, 95% CI 0·58-0·69) and T2D (0·85, 0·78-0·93) diagnosis, and increased risk of diabetic eye disease among individuals with T2D (1·20, 1·01-1·43). Modelling suggested approximately 1,019 missed prediabetes and 303 missed T2D diagnoses per 100,000 adults over 10 years. Interpretation: An ancestry enriched PIEZO1 variant is associated with lower HbA1c independent of glycaemia, reduced prediabetes and T2D diagnosis suggesting delayed detection, and increased complication risk. Reliance on HbA1c may systematically underestimate glycaemic risk in a substantial minority of south Asians. Funding: The Wellcome Trust; NIHR Research in Context: Evidence before this study: We searched PubMed from database inception to Nov 1, 2025, for studies examining PIEZO1, Glycated Haemoglobin (HbA1c) and type 2 diabetes (T2D) related outcomes. Search terms included “PIEZO1”, “haemoly*”, “hemol*”, “erythrocyte*”, “HbA1c”, “glycated haemoglobin”, “glycated hemoglobin”, “type 2 diabetes”, “prediabetes”, “retinopathy”, and related terms. HbA1c is widely used to guide prevention, diagnosis, and management of T2D, but variants affecting erythrocyte structure or lifespan can alter its relationship with glycaemia. A missense variant in PIEZO1 (rs563555492 T ), carried by one in twelve south Asians, has been associated with lower HbA1c and erythrocytic biomarkers without differences in fasting glucose and with older age at T2D diagnosis, suggesting delayed diagnosis in UK-based cohorts. However, uncertainties remain. Associations have not been replicated outside the UK to confirm generalisability. Experimental animal models suggest PIEZO1 channels may influence pancreatic insulin secretion, but this has not been evaluated in human cohorts. Finally, the potential clinical and health-economic consequences associated with this variant remain largely unexplored. Added value of this study: We replicated associations between rs563555492 T , lower HbA1c, and erythrocytic changes in a geographically distinct south Asian cohort based in South India. We found no association with fasting glucose, postprandial glucose, or C-peptide concentrations, supporting a predominantly erythrocytic mechanism. We examined the clinical and economic consequences of this variant on south Asians in a large UK population-based cohort, following introduction of HbA1c-based diagnostic criteria. Carriers experienced delayed diagnosis of prediabetes and T2D, and there was some evidence of increased risk of diabetic eye disease. In a modelled population aged 40-50 years, the variant was associated with approximately 1,019 missed prediabetes diagnoses and 303 missed T2D diagnoses per 100,000 adults over 10 years. Because prediabetes diagnosis initiates referral to prevention programmes, missed diagnoses represent lost opportunities for disease prevention. In a UK NHS setting, we estimated the associated opportunity cost to be between £970,000 - £1,390,000 per 100,000 individuals over a 10-year horizon. Implications of all the available evidence: A south Asian ancestry enriched PIEZO1 variant can disrupt the relationship between HbA1c and glycaemia and delay detection of prediabetes and T2D. Reliance on HbA1c alone may underestimate glycaemic risk in a substantial minority of individuals of south Asian ancestry, with potential implications for prevention strategies, risk of complications and health care costs. Alternative biomarkers of glycaemia or individualisation of HbA1c may help ensure timely and accurate diabetes detection in populations where this variant is common.
- Open Access
Selection-guided discovery in South Asians implicates the MAPT locus in insulin resistance
South Asians constitute 25% of the global population yet account for 33% of individuals living with type 2 diabetes (T2D) (1). Despite this burden, they remain substantially underrepresented in genome-wide association studies (GWAS), limiting discovery of ancestry-relevant disease biology (2). This limits biological insight and hampers genomic discovery. Here we integrated genome-wide signatures of recent positive selection across 13 South Asian populations (3,4) with cross-trait genetic association data (3,4). We identified 1,797 genes residing within regions under recent positive selection and prioritised 65 shared across South Asia. Selection-prioritised loci were enriched for credible sets from the largest trans-ancestry T2D GWAS and for partitioned polygenic score clusters implicated in lipodystrophy-like fat distribution, obesity and proinsulin biology. Multi-trait fine-mapping recovered established T2D loci, including RBM6 and PEPD , and identified a signal at MAPT associated with hepatic insulin resistance, erythrocytic traits and HbA1c in two independent south Asian cohorts (5–7). These findings demonstrate that signatures of recent positive selection can be integrated with genetic association data to prioritise metabolically relevant loci and provide a complementary route to genetic discovery in underrepresented populations.
Open AccessSelection-guided discovery in South Asians implicates the MAPT locus in insulin resistance
South Asians constitute 25% of the global population yet account for 33% of individuals living with type 2 diabetes (T2D) (1). Despite this burden, they remain substantially underrepresented in genome-wide association studies (GWAS), limiting discovery of ancestry-relevant disease biology (2). This limits biological insight and hampers genomic discovery. Here we integrated genome-wide signatures of recent positive selection across 13 South Asian populations (3,4) with cross-trait genetic association data (3,4). We identified 1,797 genes residing within regions under recent positive selection and prioritised 65 shared across South Asia. Selection-prioritised loci were enriched for credible sets from the largest trans-ancestry T2D GWAS and for partitioned polygenic score clusters implicated in lipodystrophy-like fat distribution, obesity and proinsulin biology. Multi-trait fine-mapping recovered established T2D loci, including RBM6 and PEPD , and identified a signal at MAPT associated with hepatic insulin resistance, erythrocytic traits and HbA1c in two independent south Asian cohorts (5–7). These findings demonstrate that signatures of recent positive selection can be integrated with genetic association data to prioritise metabolically relevant loci and provide a complementary route to genetic discovery in underrepresented populations.
- Open Access
An ancestry-enriched HNF4A variant and GP2 reveal distinct mechanisms of type 2 diabetes in exome-wide study of 13,674 cases and 41,024 controls
/ Introductory Paragraph: Type 2 diabetes (T2D) is a common and complex metabolic condition with significant heterogeneity within and across ancestries 1–4 . Compared with individuals of European ancestry (EUR), people of south Asian ancestry (SAS) have two to four-fold higher risk of T2D, develop the disease at younger ages and lower body mass index (BMI), and experience more rapid progression to complications 5–10 . Understanding the genetic basis of this is hindered by low representation of south Asians in genetic studies. Here, we perform an exome-wide association study of T2D in 13,674 cases and 41,024 controls from the Genes & Health study of British Pakistani and Bangladeshi individuals. We identify a novel rare variant in HNF4A – a canonical monogenic diabetes / MODY gene, in which missense variants would be expected to increase T2D risk. Surprisingly, HNF4A Pro437Ser is associated with a halved risk of T2D and reduced risk of diabetes-related complications but increased non-HDL cholesterol. We additionally characterise a T2D risk-increasing variant which is common only in South and East Asian ancestral groups ( GP2 Val429Met), which is associated with lower BMI and phenotypic and genetic markers of insulin deficiency. We validate our findings through replication in independent multi-ancestry cohorts, in vitro functional assays, and integration of proteogenomic analysis. These findings highlight how the study of under-represented populations can identify biological mechanisms associated with disease phenotypes enriched in those populations.
Open AccessAn ancestry-enriched HNF4A variant and GP2 reveal distinct mechanisms of type 2 diabetes in exome-wide study of 13,674 cases and 41,024 controls
/ Introductory Paragraph: Type 2 diabetes (T2D) is a common and complex metabolic condition with significant heterogeneity within and across ancestries 1–4 . Compared with individuals of European ancestry (EUR), people of south Asian ancestry (SAS) have two to four-fold higher risk of T2D, develop the disease at younger ages and lower body mass index (BMI), and experience more rapid progression to complications 5–10 . Understanding the genetic basis of this is hindered by low representation of south Asians in genetic studies. Here, we perform an exome-wide association study of T2D in 13,674 cases and 41,024 controls from the Genes & Health study of British Pakistani and Bangladeshi individuals. We identify a novel rare variant in HNF4A – a canonical monogenic diabetes / MODY gene, in which missense variants would be expected to increase T2D risk. Surprisingly, HNF4A Pro437Ser is associated with a halved risk of T2D and reduced risk of diabetes-related complications but increased non-HDL cholesterol. We additionally characterise a T2D risk-increasing variant which is common only in South and East Asian ancestral groups ( GP2 Val429Met), which is associated with lower BMI and phenotypic and genetic markers of insulin deficiency. We validate our findings through replication in independent multi-ancestry cohorts, in vitro functional assays, and integration of proteogenomic analysis. These findings highlight how the study of under-represented populations can identify biological mechanisms associated with disease phenotypes enriched in those populations.
- Open Access
- 24 September 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-10
XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestries
Background: Individuals of South and East Asian ancestry have a higher risk of type 2 diabetes, often driven by insulin deficiency due to impaired beta-cell function. The transcription factor XBP1 supports beta-cell survival by reducing cellular stress, but its role in diabetes risk and glucose regulation remains unclear. This study aimed to evaluate the impact of XBP1 expression on diabetes risk, beta-cell function, glycaemic traits, and treatment response across ancestries. Methods: We performed colocalisation analyses to test whether XBP1 expression in pancreatic islets and type 2 diabetes share causal variants. A lead variant regulating XBP1 expression was identified and analysed in two South Asian cohorts from India to assess associations with beta-cell function and glucose levels. We further assessed glycaemic control using HbA1c in cohorts of British South Asians and white Europeans. We examined the effect of the variant on drugs designed to improve insulin secretion. Results: XBP1 expression colocalises with diabetes risk in East Asians but not in white Europeans, and lower expression is associated with higher risk of diabetes. The lead SNP of the eQTL (rs7287124) is more common in East (65%) and South Asians (50%) compared to white Europeans (25%). rs7287124 is associated with lower beta-cell function using HOMA-B (P = 5 × 10−3, n = 470). In trans-ancestry meta-analyses rs7287124 is associated with 4.32 mmol/mol (95% CI: 2.60–6.04, P = 8 × 10−7) higher HbA1c. In individuals with young, non-obese onset diabetes, the trans-ancestry effect is 6.41 mmol/mol (P = 2 × 10−4). Variant carriers show impaired response to sulphonylureas. Conclusions: XBP1 expression is associated with diabetes risk with particular value in under-represented populations at risk of young, non-obese onset diabetes.
- 24 September 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-10
Open AccessXBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestries
Background: Individuals of South and East Asian ancestry have a higher risk of type 2 diabetes, often driven by insulin deficiency due to impaired beta-cell function. The transcription factor XBP1 supports beta-cell survival by reducing cellular stress, but its role in diabetes risk and glucose regulation remains unclear. This study aimed to evaluate the impact of XBP1 expression on diabetes risk, beta-cell function, glycaemic traits, and treatment response across ancestries. Methods: We performed colocalisation analyses to test whether XBP1 expression in pancreatic islets and type 2 diabetes share causal variants. A lead variant regulating XBP1 expression was identified and analysed in two South Asian cohorts from India to assess associations with beta-cell function and glucose levels. We further assessed glycaemic control using HbA1c in cohorts of British South Asians and white Europeans. We examined the effect of the variant on drugs designed to improve insulin secretion. Results: XBP1 expression colocalises with diabetes risk in East Asians but not in white Europeans, and lower expression is associated with higher risk of diabetes. The lead SNP of the eQTL (rs7287124) is more common in East (65%) and South Asians (50%) compared to white Europeans (25%). rs7287124 is associated with lower beta-cell function using HOMA-B (P = 5 × 10−3, n = 470). In trans-ancestry meta-analyses rs7287124 is associated with 4.32 mmol/mol (95% CI: 2.60–6.04, P = 8 × 10−7) higher HbA1c. In individuals with young, non-obese onset diabetes, the trans-ancestry effect is 6.41 mmol/mol (P = 2 × 10−4). Variant carriers show impaired response to sulphonylureas. Conclusions: XBP1 expression is associated with diabetes risk with particular value in under-represented populations at risk of young, non-obese onset diabetes.
- Open Access
- 26 November 2024
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 323-331
Genetic basis of early onset and progression of type 2 diabetes in South Asians
South Asians develop type 2 diabetes (T2D) early in life and often with normal body mass index (BMI). However, reasons for this are poorly understood because genetic research is largely focused on European ancestry groups. We used recently derived multi-ancestry partitioned polygenic scores (pPSs) to elucidate underlying etiological pathways British Pakistani and British Bangladeshi individuals with T2D (n = 11,678) and gestational diabetes mellitus (GDM) (n = 1,965) in the Genes & Health study (n = 50,556). Beta cell 2 (insulin deficiency) and Lipodystrophy 1 (unfavorable fat distribution) pPSs were most strongly associated with T2D, GDM and younger age at T2D diagnosis. Individuals at high genetic risk of both insulin deficiency and lipodystrophy were diagnosed with T2D 8.2 years earlier with BMI 3 kg m− 2 lower compared to those at low genetic risk. The insulin deficiency pPS was associated with poorer HbA1c response to SGLT2 inhibitors. Insulin deficiency and lipodystrophy pPSs were associated with faster progression to insulin dependence and microvascular complications. South Asians had a greater genetic burden from both of these pPSs than white Europeans in the UK Biobank. In conclusion, genetic predisposition to insulin deficiency and lipodystrophy in British Pakistani and British Bangladeshi individuals is associated with earlier onset of T2D, faster progression to complications, insulin dependence and poorer response to medication.
- 26 November 2024
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 323-331
Open AccessGenetic basis of early onset and progression of type 2 diabetes in South Asians
South Asians develop type 2 diabetes (T2D) early in life and often with normal body mass index (BMI). However, reasons for this are poorly understood because genetic research is largely focused on European ancestry groups. We used recently derived multi-ancestry partitioned polygenic scores (pPSs) to elucidate underlying etiological pathways British Pakistani and British Bangladeshi individuals with T2D (n = 11,678) and gestational diabetes mellitus (GDM) (n = 1,965) in the Genes & Health study (n = 50,556). Beta cell 2 (insulin deficiency) and Lipodystrophy 1 (unfavorable fat distribution) pPSs were most strongly associated with T2D, GDM and younger age at T2D diagnosis. Individuals at high genetic risk of both insulin deficiency and lipodystrophy were diagnosed with T2D 8.2 years earlier with BMI 3 kg m− 2 lower compared to those at low genetic risk. The insulin deficiency pPS was associated with poorer HbA1c response to SGLT2 inhibitors. Insulin deficiency and lipodystrophy pPSs were associated with faster progression to insulin dependence and microvascular complications. South Asians had a greater genetic burden from both of these pPSs than white Europeans in the UK Biobank. In conclusion, genetic predisposition to insulin deficiency and lipodystrophy in British Pakistani and British Bangladeshi individuals is associated with earlier onset of T2D, faster progression to complications, insulin dependence and poorer response to medication.
- Open Access
- 30 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 9 (6) , 536-545
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance
The efficacy of statin therapy is hindered by intolerance to the therapy, leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentrations of the drug and its metabolites. Current pharmacogenetic guidelines require sequencing of the SLCO1B1 gene, which is more expensive and less accessible than genotyping. In this study, we aimed to develop an easy, clinically implementable functional gene risk score (GRS) of common variants in SLCO1B1 to identify patients at risk of statin intolerance. A GRS was developed from four common variants in SLCO1B1. In statin users from Tayside, Scotland, UK, those with a high-risk GRS had increased odds across three phenotypes of statin intolerance [general statin intolerance (GSI): ORGSI 2.42; 95% confidence interval (CI): 1.29–4.31, P = 0.003; statin-related myopathy: ORSRM 2.51; 95% CI: 1.28–4.53, P = 0.004; statin-related suspected rhabdomyolysis: ORSRSR 2.85; 95% CI: 1.03–6.65, P = 0.02]. In contrast, using the Val174Ala genotype alone or the recommended OATP1B1 functional phenotypes produced weaker and less reliable results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (ORVal174Ala 1.99; 95% CI: 1.01–3.95, P = 0.048; ORGRS 1.76; 95% CI: 1.16–2.69, P = 0.008). For those requiring high-dose statin therapy, the high-risk GRS was more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared with Val174Ala (GSI: HRVal174Ala 2.49; 95% CI: 1.09–5.68, P = 0.03; HRGRS 2.44; 95% CI: 1.46–4.08, P < 0.001). Finally, sequence kernel association testing confirmed that rare variants in SLCO1B1 are associated with the risk of intolerance (P = 0.02). We provide evidence that a GRS based on four common SLCO1B1 variants provides an easily implemented genetic tool that is more reliable than the current recommended practice in estimating the risk and predicting early-onset statin intolerance. Schematic representation of the definition of cases and controls, common SLCO1B1 variants included in the gene risk score (GRS), and findings from the study. The GRS, based on four common SLCO1B1 variants, is more reliable than Val174Ala alone in estimating the risk and predicting early onset statin intolerance.
- 30 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 9 (6) , 536-545
Open AccessA gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance
The efficacy of statin therapy is hindered by intolerance to the therapy, leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentrations of the drug and its metabolites. Current pharmacogenetic guidelines require sequencing of the SLCO1B1 gene, which is more expensive and less accessible than genotyping. In this study, we aimed to develop an easy, clinically implementable functional gene risk score (GRS) of common variants in SLCO1B1 to identify patients at risk of statin intolerance. A GRS was developed from four common variants in SLCO1B1. In statin users from Tayside, Scotland, UK, those with a high-risk GRS had increased odds across three phenotypes of statin intolerance [general statin intolerance (GSI): ORGSI 2.42; 95% confidence interval (CI): 1.29–4.31, P = 0.003; statin-related myopathy: ORSRM 2.51; 95% CI: 1.28–4.53, P = 0.004; statin-related suspected rhabdomyolysis: ORSRSR 2.85; 95% CI: 1.03–6.65, P = 0.02]. In contrast, using the Val174Ala genotype alone or the recommended OATP1B1 functional phenotypes produced weaker and less reliable results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (ORVal174Ala 1.99; 95% CI: 1.01–3.95, P = 0.048; ORGRS 1.76; 95% CI: 1.16–2.69, P = 0.008). For those requiring high-dose statin therapy, the high-risk GRS was more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared with Val174Ala (GSI: HRVal174Ala 2.49; 95% CI: 1.09–5.68, P = 0.03; HRGRS 2.44; 95% CI: 1.46–4.08, P < 0.001). Finally, sequence kernel association testing confirmed that rare variants in SLCO1B1 are associated with the risk of intolerance (P = 0.02). We provide evidence that a GRS based on four common SLCO1B1 variants provides an easily implemented genetic tool that is more reliable than the current recommended practice in estimating the risk and predicting early-onset statin intolerance. Schematic representation of the definition of cases and controls, common SLCO1B1 variants included in the gene risk score (GRS), and findings from the study. The GRS, based on four common SLCO1B1 variants, is more reliable than Val174Ala alone in estimating the risk and predicting early onset statin intolerance.
- Open Access
Common and rare variants in SLCO1B1 are associated with statin intolerance
Background and Aims: The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1 , which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, will provide more reliable estimates of statin intolerance. Methods and Results: High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: OR GSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy OR SRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: OR SRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (OR Val174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; OR risk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HR Val174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HR risk-haplotypes 2.44 [95%CI:1.46, 4.08],pSLCO1B1 , in addition to Val174Ala, provides more reliable estimates of statin intolerance.
Open AccessCommon and rare variants in SLCO1B1 are associated with statin intolerance
Background and Aims: The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1 , which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, will provide more reliable estimates of statin intolerance. Methods and Results: High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: OR GSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy OR SRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: OR SRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (OR Val174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; OR risk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HR Val174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HR risk-haplotypes 2.44 [95%CI:1.46, 4.08],pSLCO1B1 , in addition to Val174Ala, provides more reliable estimates of statin intolerance.
- Open Access
- 24 October 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (21) , 5270
The Hedgehog Signaling Pathway in Ischemic Tissues
Hedgehog (Hh) proteins are prototypical morphogens known to regulate epithelial/mesenchymal interactions during embryonic development. In addition to its pivotal role in embryogenesis, the Hh signaling pathway may be recapitulated in post-natal life in a number of physiological and pathological conditions, including ischemia. This review highlights the involvement of Hh signaling in ischemic tissue regeneration and angiogenesis, with particular attention to the heart, the brain, and the skeletal muscle. Updated information on the potential role of the Hh pathway as a therapeutic target in the ischemic condition is also presented.
- 24 October 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (21) , 5270
Open AccessThe Hedgehog Signaling Pathway in Ischemic Tissues
Hedgehog (Hh) proteins are prototypical morphogens known to regulate epithelial/mesenchymal interactions during embryonic development. In addition to its pivotal role in embryogenesis, the Hh signaling pathway may be recapitulated in post-natal life in a number of physiological and pathological conditions, including ischemia. This review highlights the involvement of Hh signaling in ischemic tissue regeneration and angiogenesis, with particular attention to the heart, the brain, and the skeletal muscle. Updated information on the potential role of the Hh pathway as a therapeutic target in the ischemic condition is also presented.